Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

450
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
450
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

98
Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
98
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

161
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
161

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-referral laboratory completeness and diagnostic yield in an early arthritis clinic: a retrospective single-centre analysis.

Rheumatology international·2026
Same author

[An update on Behçet's syndrome].

Deutsche medizinische Wochenschrift (1946)·2023
Same author

[Involvement of the inner ear in autoimmune/autoinflammatory diseases: MRI characteristics].

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2022
Same author

Tocilizumab for the Treatment of Familial Mediterranean Fever-A Randomized, Double-Blind, Placebo-Controlled Phase II Study.

Journal of clinical medicine·2022
Same author

[Imaging findings in abdominal polyarteritis nodosa and its complications].

RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin·2022
Same author

Sexual dysfunction and depression in Behçet's disease in comparison to healthy controls.

Rheumatology international·2021

Related Experiment Video

Updated: Jul 4, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K

[An update on Behçet's syndrome].

Theodoros Xenitidis1, Jörg Christoph Henes1

  • 1Medizinische Klinik II (Hämatologie/Onkologie/Klinische Immunologie/Rheumatologie), Vaskulitiszentrum Süd, Universitätsklinikum Tübingen, Tübingen.

Laryngo- Rhino- Otologie
|February 8, 2024
PubMed
Summary

Behçet's syndrome is a rare systemic vasculitis with diverse symptoms. Recent advancements include new therapies for ocular and oral manifestations, but more treatments are needed.

Area of Science:

  • Rheumatology
  • Immunology
  • Systemic Vasculitis

Background:

  • Behçet's syndrome (BS) is a rare systemic vasculitis affecting various vessels.
  • It presents with diverse clinical manifestations, posing diagnostic and therapeutic challenges.
  • Key symptoms include oral aphthae, genital aphthae, skin, and eye lesions, with potential for severe organ involvement.

Purpose of the Study:

  • To review recent findings in Behçet's syndrome.
  • Focus on epidemiology, immunopathogenesis, genetics, clinical findings, and therapy.
  • Emphasize clinical relevance for diagnosis and treatment.

Main Methods:

  • Literature review of recent advancements in Behçet's syndrome.
  • Analysis of epidemiological data, immunopathogenesis, and genetic factors.

More Related Videos

Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.3K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.2K

Related Experiment Videos

Last Updated: Jul 4, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K
Iris Fixation via External Pentagram Suturing
05:22

Iris Fixation via External Pentagram Suturing

Published on: May 5, 2022

1.3K
Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
06:15

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

1.2K
  • Evaluation of current clinical findings and therapeutic strategies, including recent drug approvals.

    • Main Results:

    • Updated European League Against Rheumatism (EULAR) recommendations provide treatment guidance.
    • Adalimumab approved for ocular involvement (2016); Apremilast approved for oral aphthae (2020).
    • Significant need for novel therapeutic agents remains.

    Conclusions:

    • Behçet's syndrome management requires interdisciplinary collaboration.
    • Therapy is guided by the primary organ involvement.
    • Ongoing research is crucial for developing new treatments for this complex condition.